Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study

References

• Maynadie M, Girodon F, Manivet-Janoray I, et al. Twenty-five years of epidemiological recording on myeloid malignancies:data from the specialized registry of hematologic malignancies of Cote d’Or (Burgundy, France). Haematologica 2011;96:55–61.
   PubMed Web of Science ®Google Scholar
• Maynadie M, De Angelis R, Marcos-Gragera R, et al. Survival of European patients diagnosed with myeloid malignancies:a HAEMACARE study. Haematologica 2013;98:230–238.
   PubMed Web of Science ®Google Scholar
• Phekoo KJ, Richards MA, Moller H, et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006;91:1400–1404.
   PubMed Web of Science ®Google Scholar
• Visser O, Trama A, Maynadie M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012;48:3257–3266.
   PubMed Web of Science ®Google Scholar
• Percy C, Van Holten V, Muir C. International classification of diseases for oncology: ICD-O. 2nd ed. Geneva: World Health Organization; 1990.
   Google Scholar
• Fritz AG. International classification of diseases for oncology: ICD-O. 3rd ed. Geneva: World Health Organization; 2000.
   Google Scholar
• Jaffe ES, Harris NL, Stein H, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010;102:83–87.
   PubMedGoogle Scholar
• Monnereau A, Troussard X, Belot A, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer 2013;132:2378–2387.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 2012;30:2995–3001.
   PubMed Web of Science ®Google Scholar
• Price GL, Davis KL, Karve S, et al. Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 2014;9:e90299.
   PubMed Web of Science ®Google Scholar
• Derolf AR, Kristinsson SY, Andersson TM, et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009;113:3666–3672.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Maziarz RT. Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used? Mayo Clin Proc 2006;81:404–416.
   PubMed Web of Science ®Google Scholar
• Pavlu J, Szydlo RM, Goldman JM, et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011;117:755–763.
   PubMed Web of Science ®Google Scholar
• Tyczynski JE, Démaret E, Parkin DM, editors. Standards and guidelines for cancer registration in Europe: the ENCR recommendations, vol. I. Lyon: IARC; 2003.
   Google Scholar
• HAEMACARE Working Group. Manual for coding and reporting haematological malignancies. Tumori 2010;96:i–A32.
   PubMedGoogle Scholar
• Osca-Gelis G, Puig-Vives M, Saez M, et al. Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 2013;98:e95–e97.
   PubMed Web of Science ®Google Scholar
• Perme MP, Stare J, Esteve J. On estimation in relative survival. Biometrics 2012;68:113–120.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266.
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005;106:3658–3665.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse:results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385–400.
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52.
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109: 1536–1542.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Taussig DC, Davies AJ, Cavenagh JD, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003;21:3060–3065.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895–3903.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119: 1981–1987.
   PubMed Web of Science ®Google Scholar
• Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008;22:1813–1817.
   PubMed Web of Science ®Google Scholar
• Osca-Gelis G, Puig-Vives M, Saez M, et al. Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993–2007. Leuk Res 2012;36:1262–1266.
   PubMed Web of Science ®Google Scholar